Dyadic International, Inc.
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021.
Conference Call Information
Date: Thursday, August 12, 2021
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 888-506-0062 International: 973-528-0011
Webcast Link: https://www.webcaster4.com/Webcast/Page/2031/42318
An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com for a limited time. To access the replay of the webcast, please follow the webcast link above. A dial-in replay of the call will also be available to those interested. To access the replay, please dial Toll Free: 877-481-4010 (U.S. or Canada) or International: 919-882-2331 (International) and enter replay pass code: 42318.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company that is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing, which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding Dyadic's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Forward-looking statements generally can be identified by use of the words "expect," "should," "intend," "aim," "anticipate," "believe," "will," "project," "may," "might," "potential," "pursue," or "continue" and other similar terms or variations of them or similar terminology. However, not all forward-looking statements contain these words. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to implement and successfully carry out Dyadic's and third parties' research and development efforts; (4) the pharmaceutical and biotech industry, governmental regulatory and other agencies' willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (5) other factors described in the Company's most recent filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this press release are made only as of the date hereof, and Dyadic does not intend, and except as required by law assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com
SOURCE: Dyadic International, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657685/Dyadic-to-Report-Second-Quarter-2021-Financial-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Announces Q1 2025 Results1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three months ended March 31, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS First quarter consolidated energy production of 216,344 MWh, compared to 213,434 MWh in the first quarter last year. The modest increase is mainly attributable to the production of the Puerto Rican wind farm which was acquired on March 3, 2025 and did not contribute to consolidated energy production during the comparative quarter of 2024. The Company generated $20.3 million in revenue
Polaris Renewable Energy Declares Quarterly Dividend1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on May 23rd to shareholders of record at the close of business on May 12th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's operations inclu
Sensiba Acquires AssuranceLab to Fuel Innovation in Global Cybersecurity and Risk Assurance30.4.2025 18:00:00 CEST | Press release
SAN RAMON, CA AND SYDNEY, AUSTRALIA / ACCESS Newswire / April 30, 2025 / Sensiba LLP, a Top-75 U.S. accounting and consulting firm, is pleased to announce the acquisition of AssuranceLab Pty. Ltd., a high-growth cybersecurity audit and risk assurance firm headquartered in Australia, with operations across the Americas, APAC, and EMEA. This milestone expands Sensiba's international reach and deepens its security, privacy, and compliance framework capabilities. Together, the combined firm now supports over 2,300 startup and technology-driven enterprise clients worldwide-providing streamlined, high-quality audits across more than 15 compliance standards, including SOC 2, ISO/IEC 27001, HIPAA, CSA STAR, and HITRUST. "We're honored to welcome AssuranceLab to Sensiba. Their reputation in the market is well-earned, driven by innovation, credibility, and a commitment to raising the bar for cybersecurity audits. What makes this such a strong fit is the alignment across our values and client ser
BitMobile's Phenix X Blockchain Phone Excels in Zambia with Major Marketing Push30.4.2025 11:00:00 CEST | Press release
LUSAKA, ZM / ACCESS Newswire / April 30, 2025 / BitMobile, dedicated to bringing cutting-edge mobile technology to emerging markets, has announced the launch of a massive countrywide marketing campaign across Zambia. This extensive effort is designed to reach every corner of the nation, celebrating the Phēnix X blockchain phone's growing popularity and introducing its transformative capabilities to even more Zambians. The Phēnix X has quickly become a sought-after device in Zambia, recognized for its innovative features, robust security, and potential to unlock new opportunities. This latest campaign aims to build on that momentum, making the Phēnix X visible and accessible from bustling city centers to remote communities. "We've seen incredible enthusiasm for the Phēnix X in Zambia already," said Brian Maw, CEO of Finnovant, the parent company of BitMobile. "This nationwide campaign is about meeting that demand head-on and showing everyone why the Phēnix X is the phone for the future.
BitMobile Pty Ltd and Reality Network Announce Strategic Partnership, Bringing Preloaded DeFi Earning Node Application to Phēnix X Users Globally30.4.2025 11:00:00 CEST | Press release
CAPRE TOWN, SOUTH AFRICA / ACCESS Newswire / April 30, 2025 / BitMobile, the driving force behind the revolutionary Phēnix X Blockchain phone in South Africa and emerging markets, and Reality Network, a pioneer in decentralized blockchain technology, today announced a strategic partnership that highlights the Reality Network node app preloaded onto the Phēnix X smartphone. This collaboration marks a significant engagement in bringing accessible Decentralized Finance (DeFi) earning opportunities directly to customers in each country and territory, particularly empowering communities in emerging markets. The Phēnix X, a device designed to be a catalyst for financial inclusion and digital literacy, comes preloaded with the Reality Network node application, allowing owners to easily participate in decentralized networks and earn cryptocurrency by simply contributing their device's unused computing power. This innovative approach transforms the smartphone into a valuable asset for generatin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom